Parameter
| Biomarker | KRAS mutant (G12D/V/R) | Full name | Kirsten rat sarcoma viral oncogene homolog mutant | Molecular Type | Nucleic acid (DNA) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Treatment options and prognosis assessment | ||
| Disease | Pancreatic Cancer | Disease Subtypes | / | ||
| Organ | Pancreas | Test Sample / Technology Platform | Organization, ctDNA (next-generation sequencing) | ||
| Pathobiological Mechanisms | Is the most common PDAC KRAS mutations drive events (> 90%), lead to protein activation, drive MAPK signaling pathways such as promoting tumor proliferation and metabolic reprogramming | ||||
| Clinical Availability Status | Clinical can be used as a guide (treatment) : used for screening of targeted therapy, such as KRAS G12C inhibitors for patients | ||||
| Notes and Dynamics | It is a key event in the early development of PDAC and has been detected in precancerous lesions (PanIN). Its mutation status can guide precise treatment strategies | ||||